Equities research analysts expect that Kura Oncology, Inc. (NASDAQ:KURA) will report ($0.36) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kura Oncology’s earnings, with estimates ranging from ($0.41) to ($0.32). Kura Oncology reported earnings per share of ($0.38) during the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.57) to ($1.49). For the next year, analysts anticipate that the firm will report earnings of ($1.72) per share, with EPS estimates ranging from ($2.18) to ($1.42). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Kura Oncology.
Several equities analysts have recently issued reports on KURA shares. Zacks Investment Research cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. BidaskClub raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Cann reissued a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Citigroup boosted their price objective on Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Finally, Wedbush started coverage on Kura Oncology in a report on Wednesday, December 20th. They issued an “outperform” rating and a $19.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Kura Oncology currently has a consensus rating of “Buy” and a consensus price target of $21.67.
Shares of Kura Oncology (KURA) traded up $1.70 during mid-day trading on Friday, hitting $22.75. The stock had a trading volume of 870,692 shares, compared to its average volume of 380,400. The firm has a market cap of $569.56, a PE ratio of -14.68 and a beta of 4.94. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a fifty-two week low of $5.90 and a fifty-two week high of $22.90.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in Kura Oncology in the 3rd quarter worth about $802,000. Alethea Capital Management LLC raised its holdings in Kura Oncology by 15.5% in the 3rd quarter. Alethea Capital Management LLC now owns 111,673 shares of the company’s stock worth $1,670,000 after purchasing an additional 15,000 shares during the period. EAM Investors LLC acquired a new position in Kura Oncology in the 3rd quarter worth about $2,884,000. TIAA CREF Investment Management LLC acquired a new position in Kura Oncology in the 2nd quarter worth about $385,000. Finally, California State Teachers Retirement System raised its holdings in Kura Oncology by 24.5% in the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after purchasing an additional 6,200 shares during the period. 63.10% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “-$0.36 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/16/0-36-eps-expected-for-kura-oncology-inc-kura-this-quarter.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Get a free copy of the Zacks research report on Kura Oncology (KURA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.